Screener
Ligand Pharmaceuticals LGND Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 5,000 shares authorized; zero issued and outstanding at June 30, 2026 and December 31, 2025 | — | — |
| Common stock, $0.001 par value; 60,000 shares authorized; 19,920 and 19,774 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | 20 | 20 |
| Additional paid-in capital | 379,769 | 400,649 |
| Accumulated other comprehensive income | 4,476 | 8,455 |
| Retained earnings | 583,251 | 608,088 |
| Total stockholders’ equity | 967,516 | 1,017,212 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ligand Pharmaceuticals's common stock?
- Ligand Pharmaceuticals (LGND) reported common stock of 60M in Q2 2026.
- How has Ligand Pharmaceuticals's common stock changed year-over-year?
- Ligand Pharmaceuticals's common stock decreased by 0.0% year-over-year, from 60M to 60M.
- What is the long-term trend for Ligand Pharmaceuticals's common stock?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's common stock has grown at a 418.6% compound annual growth rate (CAGR), from 16K to 60M.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Ligand Pharmaceuticals's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude